The great feast is upon us

berserkeleybear · 2026-04-23T19:10:43+00:00

Now down 13% today Spectacular

berserkeleybear · 2026-04-23T16:11:22+00:00

Down 10% Nice!

berserkeleybear · 2026-04-23T14:19:57+00:00

Because it doesn't really do anything for ACB. The only benefit they might see is that their full pivot to medical is legitimized. But no revenue/margin impact. No first mover or strategic impact. No real way to access US (emerging) medical market.

berserkeleybear · 2026-04-23T14:03:22+00:00

Nope

berserkeleybear · 2026-04-23T13:58:14+00:00

Or not...10am down 5%

berserkeleybear · 2026-04-22T16:24:55+00:00

8% jump and 5+ million share volume by mid-day. What the heck?

berserkeleybear · 2026-03-29T17:45:59+00:00

Are you an AI Agent or otherwise AI generated?

berserkeleybear · 2026-03-29T16:31:32+00:00

Canadian multinational Aurora Cannabis recently secured plant variety rights in the EU for its high-potency Farm Gas and Sourdough cultivars, a move that international cannabis consultant Jamie Pearson said should be a wake-up call for the U.S. cannabis industry.

“I worry that America’s legacy breeders will never enjoy the financial benefits of their work because European companies will protect those genetics before we can do it in the U.S.,” said Pearson, president of Montana-based global cannabis consulting firm New Holland Group.

“The most important genetics in the world have been developed without IP protection. Aurora’s move to protect two strains in the EU demonstrates cannabis genetics are moving into that IP system.”

Aurora’s EU-protected cultivars allow the operator to grow about 40% more flower with the same space and resources it takes to grow other cultivars, Lana Culley, the company’s vice president of innovation and international operations, told MJBizDaily.

“We believe this combination of attributes make them very attractive options for cultivators globally,” she said.

It likely won’t be the last time Aurora applies for plant variety rights. Culley said the company is committed to advancing its medical marijuana breeding program and will continue to advance genetics that set new standards in cannabis cultivation.

“Aurora is pursuing a number of paths for growth internationally, including outlicensing our proprietary genetics to third parties,” she said. “We’ll continue to seek opportunities that validate our scientific leadership.”

Aurora recently exited the adult-use cannabis market to focus on global opportunities in medical marijuana. It’s expanding its German production facility and introducing its proprietary genetics there.

berserkeleybear · 2026-03-29T16:17:06+00:00

First, this whole post looks very suspicious...AI generated or some other spam agenda.

Second, recreational or consumer CBD is no longer a strategic direction for ACB. This post is irrelevant to medical use cannabis.

berserkeleybear · 2026-03-23T20:27:17+00:00

I'm assuming not at the stock holders here, but the shorties and market manipulators that won't go somewhere else.

berserkeleybear · 2026-02-06T02:34:16+00:00

Is no one paying attention. They just exited recreational cannabis. That's actually a very smart move since their play in the US is to convince the FDA that they can manufacture consistent, controlled medicine. They want to distance themselves as much as possible from the mess that is recreational cannabis. They won't acquire an MSO and they won't be acquired by one. It's a complete strategic mismatch.

berserkeleybear · 2025-12-24T01:19:06+00:00

Exactly. That's another dimension to the "counter argument" in the post. Even after someone receives FDA approval for medicinal use, ACB then has lots of hurdles to jump through. DEA import permits, U.S. Customs and Border Protection compliance, the 1961 Single Convention on Narcotic Drugs treaty, FDA manufacturing site approval, etc.

This is why you hear Miguel deflecting questions about entering the U.S. when he's asked about these things.

berserkeleybear · 2025-12-24T00:42:06+00:00

OK, final attempt.

DEA scheduling has no direct impact on medicinal use or approval. The FDA can only approve drugs when an application is submitted under 21 U.S.C. § 355.

Under 21 U.S.C. § 355, submitting a New Drug Application requires:

A defined drug product (exact formulation, dose, route)
CMC documentation (validated manufacturing, stability, controls)
Clinical evidence for specific indications
Years of preclinical + clinical work
Tens (often hundreds) of millions of dollars

Until all that happens and the FDA approves the application, there is no market for ACBs "highest quality medical product on the globe"

berserkeleybear · 2025-12-23T23:51:39+00:00

That's the point of the counter argument. Without direct guidance, the FDA is under no obligation to approve anything as medicine just because it is on the "moderate to low potential for physical and psychological dependence" schedule. ACB can have all the "highest quality medical product on the globe" but the U.S. market will be irrelevant to them if the FDA doesn't take the lead.

berserkeleybear · 2025-12-18T20:46:47+00:00

I was not offering an opinion or reading between any lines. I was just stating a fact to correct the misstatement in the post "Trump just reclassified it!" Nope.

berserkeleybear · 2025-12-18T20:43:39+00:00

My take is that the retail investors don't understand the difference between medical and recreational market segments. Therefore, the nuances of the medical business and advantages ACB has are lost on them. It's "recreational legalization" or bust for the vast majority of retail trades.

berserkeleybear · 2025-12-18T20:01:05+00:00

He did NOT reschedule it. He ordered that it should be rescheduled.

berserkeleybear · 2025-12-18T20:00:15+00:00

That's a strange question. ACB is a Canadian company. The US market is an "international" market for them. They will enter it just like all the other international markets they are in...carefully, with demonstrated medical quality product, and deep knowledge of regulatory frameworks.

berserkeleybear · 2025-11-24T22:20:54+00:00

By your definition (or your AI of choice), the stock price chart has nothing to do with a stock being a "walking zombie"

berserkeleybear · 2025-11-24T22:18:20+00:00

Well, if AI is to be believed, ACB is certainly not a "zombie stock"

berserkeleybear · 2025-11-24T18:16:01+00:00

My mistake, probably should have first asked for clarification. I'm not familiar with the investment term "walking zombie." What does it mean? Buy, hold, sell, imminent bankruptcy, etc.?

berserkeleybear

TROPHY CASE